We are a biotech startup in the San Francisco Bay Area
founded in February 2017. We focus on developing complex antibodies
with enhanced efficacy, safety, and manufacturability features against
difficult-to-treat diseases including cancer, infectious diseases, and CNS
diseases, by combining conventional approaches with computer-aided
antibody design (CAAD). Our founder and lead scientists have extensive
expertise in the fields of therapeutic antibody discovery, lead selection,
engineering, humanization, and optimization.

Our goal is to close the gap between antibody discovery and therapeutic
antibody development by developing the next generation of therapeutic
antibodies. We believe in quality-by-design and have established several
CAAD-based unique technology platforms for antibody development and
are in the process of developing more platforms and therapeutics.

3541 Investment Blvd. Suite 3,
Hayward, CA 94545 USA